MedTrace Logo

Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer

NCT03215459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-01-05

No results posted yet for this study

Summary

Cardiopulmonary exercise testing (CPET) has been shown to be superior to American Society of Anaesthetist classification (ASA) in predicting peri-operative risk. The most common performance status used is the World Health Organisation (WHO) (0-4), with a clinician agreed differentiation of the subsets of 0-2 and 3-4; variability also exists within these subsets.

With this there rises a concern that fit older patients may not be offered appropriate chemotherapy treatment. This observational study will assess whether cardiopulmonary exercise testing (CPET) offers additional benefit over that of WHO Performance status (PS) in the assessment of patients fitness for palliative chemotherapy for pancreatic cancer, by identifying those patients who might survive longer and tolerate chemotherapy better, thus predicting their outcome.

Conditions

Interventions

DEVICE

Cardiopulmonary Exercise Test

Cardiopulmonary Exercise Test

Sponsors & Collaborators

  • University of Liverpool Cancer Research Centre

    collaborator OTHER

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Daniel Palmer, Professor · Clatterbridge

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-08-31
Completion
2023-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03215459 on ClinicalTrials.gov